Evaluation of Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer and Analysis of Baseline Characteristics Between Patients With or Without PSA Value of 0.2 ng/dl.

Prostate cancer remains the most common malignancy in men in Europe. Over the last two decades, the treatment landscape for both localized and metastatic prostate cancer has been revolutionized. For patients with metastatic castration-sensitive prostate cancer (mCSPC), the primary treatment objectives are to delay progression to metastatic castration-resistant prostate cancer (mCRPC) and to improve overall survival (OS). Although patients with PC may initially respond to androgen deprivation therapy (ADT), progression to castration resistance occurs in 10-20% of patients within 5 years.
Primary ADT has been the standard of care for over 50 years. However, recent advancements have shifted treatment from ADT monotherapy for all mHSPC/mCRPC patients to more intensive approaches, which include combinations of ADT with new androgen receptor pathway inhibitors (ARPIs), chemotherapy, or both, tailored to tumor characteristics such as metastatic burden.
In clinical practice, a reduction in prostatic specific antigen (PSA) levels from baseline is commonly used to monitor disease control, particularly in the castration sensitive phase (both early and metastatic). For patients with mCSPC, a decrease in PSA levels signifies that the treatment is effective. Moreover, the depth, time and duration of this PSA reduction are linked to better clinical outcomes, including OS. Although more patients achieved an optimal PSA response with intensified ADT (with ARPI or docetaxel), those with a suboptimal response have a significantly worse survival rate. Several key studies have demonstrated that achieving undetectable PSA (≤0.2 ng/mL) is associated with better OS, irrespective of subgroups.
This study aims to evaluate patient survival based on PSA response and to describe baseline characteristics among patients with or without PSA response. Specifically, patients will be divided into two groups based on the achievement of PSA values ≤ 0.2 ng/dl, and overall survival (OS) and progression free survival (PFS) for each group will be evaluated. Clinical and laboratory information at baseline will be compared between the two groups. Baseline characteristics considered are histology, Gleason score, stage of disease, presence of genetic alterations, PSA values, sites and number of metastases, de novo or metachronous disease, high/low risk disease, high/low volume disease.

Start Date20 Dec 2024

Sponsor / Collaborator-

NCT06614348

/ Not yet recruitingPhase 2IIT

A Randomized Controlled Study of Prednisolone Acetate Eye Drops for Pain Intervention in Second Eye Cataract Surgery

This study aims to evaluate the efficacy, safety, and potential mechanisms of prednisolone acetate eye drops for pain management in patients undergoing second-eye surgery for age-related cataracts.
Researchers will compare prednisolone acetate eye drops to sodium hyaluronate eye drops to see if prednisolone acetate eye drops work to relieve intraoperative and postoperative pain during second-eye cataract surgery.
Participants will:
1. Receive prednisolone acetate eye drops or sodium hyaluronate eye drop four drops within 2 hours before cataract surgery
2. Finish cataract surgery and routine postoperative follow-up
3. Pain questionnaire completed after cataract surgery

Start Date08 Oct 2024

Sponsor / Collaborator

Shanghai First People's Hospital

CTRI/2024/06/069179

/ Not yet recruitingPhase 4IIT

A comparative study of the effectiveness of ropivacaine vs lignocaine both with methyl prednisolone acetate in peripheral nerve block at wrist in complex regional pain syndrome type 1 - NIL

Start Date29 Jun 2024

Sponsor / Collaborator-

100 Clinical Results associated with Prednisolone Acetate

100 Translational Medicine associated with Prednisolone Acetate

100 Patents (Medical) associated with Prednisolone Acetate

1,532

Literatures (Medical) associated with Prednisolone Acetate

01 Mar 2025·Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy

A Green analytical method for simultaneous determination of dexamethasone sodium phosphate and prednisolone acetate in veterinary formulations using UV spectroscopy and dimension reduction algorithms

Article

Author: Ibrahim, Marwan A. ; Ibrahim, Ahmed M ; Algohary, Ayman M. ; Ibrahim, Marwan A ; Ibrahim, Ahmed M. ; Algohary, Ayman M ; Al-Ghamdi, Youssef O. ; Al-Ghamdi, Youssef O

Precise determination of veterinary pharmaceutical concentrations represents a critical foundation for delivering safe and efficacious animal healthcare interventions. Two synthetic glucocorticoids - dexamethasone sodium phosphate (DXM) and prednisolone acetate (PRD) - are extensively employed in veterinary medicine due to their potent anti-inflammatory capabilities. Our research presents a novel, cost-effective, and environmentally sustainable analytical methodology that enables simultaneous quantification of DXM and PRD within binary veterinary formulations. The method synergistically combines UV spectroscopy with dimension reduction algorithms (DRAs), representing a significant advancement in pharmaceutical analysis. A comprehensive evaluation of seventeen DRAs was conducted using four distinct performance metrics: mean squared error (MSE), mean absolute error (MAE), median absolute error (MedAE), and coefficient of determination (R²). Among the assessed algorithms, mini-batch sparse principal component analysis demonstrated superior predictive accuracy for this specific analytical challenge. The developed method was validated using the accuracy profile approach, yielding results that confirm its satisfactory accuracy. An ecological impact assessment was conducted using five greenness evaluation tools: the Green Solvent Selection Tool (GSST), National Environmental Methods Index (NEMI), Green Certificate modified Eco-Scale, carbon footprint analysis, and the Modified GAPI (MoGAPI). In addition, whiteness was evaluated with Red-Green-Blue 12 (RGB 12) algorithms. The proposed method showed elevated GSST scores and a greener profile according to NEMI. The calculated carbon footprint was 0.0006 kg CO₂ equivalent per sample, with a Green Certificate modified Eco-Scale score of 84, a MoGAPI score of 81, and a whiteness assessment of 90.1 by the RGB12 algorithm. Statistical comparison between the proposed spectrophotometric method and a previously reported HPLC method for pharmaceutical dosage form analysis revealed no statistically significant differences at the 95 % confidence level. This study underscores the innovative combination of UV spectroscopy with dimension reduction algorithms, presenting substantial improvements over traditional UV techniques for drug analysis. This method enhances both the efficiency and accuracy of active ingredient determination in pharmaceutical dosage forms while also supporting environmental sustainability.

01 Jan 2025·Annals of African Medicine

Bilateral Corneal Endotheliitis Following Corneal Cross-linking with Riboflavin and Ultraviolet A

Article

Author: Al-othman, Ahmed Y. ; Algamdi, Saleh S.

This case report aims to document a case of bilateral endotheliitis occurring shortly after riboflavin-assisted cross-linking (CXL) in a young male patient with progressive keratoconus. The objective is to identify potential risk factors, treatment strategies, and outcomes while considering relevant literature on similar cases. A male in his late adolescence with bilateral progressive keratoconus underwent bilateral CXL using riboflavin and ultraviolet A light exposure. Postoperatively, the patient received moxifloxacin drops, prednisolone acetate drops, and artificial tears. Seven days later, the patient presented with decreased vision, photophobia, and corneal findings consistent with endotheliitis. Treatment with prednisolone acetate and moxifloxacin eye drops was initiated. Two months later, visual acuity deteriorated, but anterior slit-lamp findings improved, and the intraocular pressure measurement was high. Prednisolone acetate was tapered, whereas loteprednol etabonate gel, brimonidine eye drops, and cyclosporine eye drops were initiated. After 7 months, visual acuity improved, and endotheliitis resolved, although mild residual central haze persisted. This case highlights the occurrence of acute idiopathic endotheliitis following routine CXL and its successful management. Although limited cases have been reported, a standardized treatment protocol is lacking. In our patient, the utilization of loteprednol etabonate gel, cyclosporine eye drops, brimonidine eye drops, and regular follow-up examinations led to improved clinical findings and visual acuity. Further studies are warranted to establish optimal treatment approaches for similar cases of endotheliitis following CXL.

01 Jan 2025·RETINAL Cases & Brief Reports

CLOSURE OF A CHRONIC TRAUMATIC MACULAR HOLE AFTER PHACOEMULSIFICATION SURGERY

Article

Author: Feng, Shu ; Ohan, Masis A ; Bonnell, Alyssa C

Purpose:To report a case of chronic traumatic macular hole closure after an uncomplicated phacoemulsification surgery.Methods:Retrospective chart review with optical coherence tomography imaging.Results:Forty-two-year-old woman with a 20-year history of a traumatic macular hole and cataract in the right eye underwent an uncomplicated phacoemulsification surgery. After surgery, the patient was prescribed prednisolone acetate 1% four times per day, which was tapered off by postoperative month 1. By postoperative month 1, the full-thickness macular hole had closed.Conclusion:This unique case illustrates the closure of a full-thickness macular hole after cataract surgery. We hypothesize that the closure of the macular hole was aided by the use of topical steroids in the postoperative period, allowing for resolution of the cystic intraretinal fluid and hole closure.

News (Medical) associated with Prednisolone Acetate

29 Apr 2024

·www.biospace.com

Bausch + Lomb Announces Presentation of New Data at the Association for Research in Vision and Ophthalmology Annual Meeting

21 Poster Presentations include Evaluations of Consumer, Pharmaceutical, Surgical and Vision Care Products and Pipeline Programs, Including a Novel Dry Eye Nutritional Supplement VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of 21 scientific poster presentations during the Association for Research in Vision and Ophthalmology Annual Meeting, which will take place in Seattle May 5-9, 2024. The posters highlight the results of studies evaluating consumer, pharmaceutical, surgical and vision care products from the company’s broad eye care portfolio, as well as pipeline innovations. These include a novel daily nutritional supplement formulated to address dry eye symptoms, which is the focus of two posters as well as a paper published recently in Frontiers in Ophthalmology. “We’re focused on supporting research that advances scientific knowledge of our products and fosters the development of new innovations to serve the holistic needs of eye care professionals and consumers,” said Yehia Hashad, MD, executive vice president, Research & Development and chief medical officer, Bausch + Lomb. “The breadth of data being presented at this meeting, as well as the recent publication evaluating our novel nutritional supplement for dry eyes, Blink™ NutriTears®, underscore this ongoing commitment.” Following is a complete list of titles and lead authors for each of these posters: “Analysis of Glare and its Impact on Retinal Image Quality in Intraocular lenses.” Hosten et al. “A Natural Language Processing Approach to Identify Patients with Uveitic Macular Edema in the IRIS® Registry.” Jin et al. “Clinical Evaluation of a Multi-Ingredient Oral Supplement on Dry Eye Symptoms and Tear Volume.” Barbour et al. “Clinical Evaluation of a Novel Lipid-Containing Eye Drop.” Yassine et al. “Comparison of Clinical Studies from the US and India of a Multi-Ingredient Oral Supplement.” Ryan et al. “Comparison of a Novel Lipid Nano-Emulsion Eye Drop with an Existing Lubricating Eye Drop.” Morrow et al. “Development of an In Vitro Assay to Evaluate the Antioxidant Effects of Erythritol and Glycerin in Human Corneal Epithelial Cells.” VanDerMeid et al. “Effects of Perfluorohexyloctane on the Ocular Pharmacokinetics of Latanoprost and Prednisolone Acetate After Topical Administration to Rabbits.” Cavet et al. “Effects of Perfluorohexyloctane on Corneal Healing in an Ex Vivo Study of Rabbit Corneas.” Alexander et al. “Efficacy of Perfluorohexyloctane Ophthalmic Solution in Patients with Dry Eye Disease Stratified by Baseline Severity.” Sheppard et al. “Enhancing Silicone Oil Removal Efficiency: A Comparative Study of Ultrasonic Vitrectomy Handpieces and Conventional Methods.” Higgins et al. “Evaluating a Novel Contact Solution Among Hydrogen Peroxide Lens Care Users.” Shahidi et al. “Evaluation of the Efficacy of a Novel Preservative-Free Formulation of Brimonidine Tartrate Ophthalmic Solution.” DiVito et al. “Evaluation of Intermediate-Range of Focus with New Monofocal Plus IOLs.” Lau et al. “Evaluation of the Safety of a Novel Preservative-Free Formulation of Brimonidine Tartrate Ophthalmic Solution.” Vollmer et al. “Impact of Pupil Size on Vision Performance of a New Multifocal Daily Disposable Contact Lens.” Reindel et al. “In-Home Use Test of a Novel Contact Lens Solution in Contact Lens Wearers on the Verge of Dropout.” Rah et al. “Intraocular Pressure Optimized Performance Settings with Posterior Adaptive Fluidics (PAF), and 25 Gauge 25,000 cpm Dual-Action Vitrectomy Cutters.” Papour et al. “Phaco Longitudinal Mode Heat Generation, a Two-System Efficiency Comparison Study.” Dickerhoff et al. “Preclinical Toxicity Pro Perfluorohexyloctane Ophthalmic Solution.” Vittitow et al. “Predictive Modeling of Clinical Performance of Novel Trifocal IOL.” Venkateswaran et al. About Bausch + Lomb Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit and connect with us on X, LinkedIn, Facebook and Instagram. Forward-looking Statements This news release may contain forward-looking statements, which may generally be identified by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “will,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb’s filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law. © 2024 Bausch + Lomb.

28 Apr 2023

·www.globenewswire.com

Ocular Therapeutix™ To Present Data at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

BEDFORD, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced multiple scientific presentations at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting being held May 5-8 in San Diego, California. “We are thrilled that the data presented this year at ASCRS continue to highlight DEXTENZA® and its potential to address real world issues with compliance and improper self-administration of eye drops,” commented Rabia Gurses Ozden, MD, Chief Medical Officer of Ocular Therapeutix. “The data being presented demonstrates, not only the potential of DEXTENZA, but also the ability of our proprietary hydrogel technology to provide solutions for many unmet needs associated with multiple ocular conditions.” Presentations at ASCRS: Title: Safety and Effectiveness Comparison of Hydrogel-Based Intracanalicular Dexamethasone Insert Placement in the Lower Versus Upper PunctumSession Title: ASCRS Electronic Posters (On-Demand)Presenter: Patrick L Spencer, DO Title: Thermal Pulsation Therapy with Dextenza Versus Prednisolone Acetate or Sham for Meibomian Gland Dysfunction with Inflammation (Investigator Initiated Trial sponsored by Ocular Therapeutix)Session Title: Ocular Surface Disease IIISession Date/Times: Sunday, May 7, 2023 at 2:10 PM-2:15 PM ET | 11:10 PM-11:15 PM PTLocation: SDCC – Upper Level 1BPresenter: Lisa M Nijm, MD, JD, ABO Title: Prospective Evaluation of Eye Drop Self-Administration Accuracy in a Real-World Patient PopulationSession Title: Cornea Diagnostics and StudiesSession Date/Times: Sunday, May 7, 2023 at 5:00 PM-5:05 PM ET | 2:00 PM-2:05 PM PTLocation: SDCC – Upper Level, Room 1APresenter: Alison D Early, MD, ABO About Ocular Therapeutix, Inc. Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix’s first commercial drug product, DEXTENZA®, is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. Ocular Therapeutix’s earlier stage development assets include: OTX-TKI (axitinib intravitreal implant), currently in Phase 1 clinical trials for the treatment of wet AMD and diabetic retinopathy; OTX-TIC (travoprost intracameral implant), currently in a Phase 2 clinical trial for the treatment of primary open-angle glaucoma or ocular hypertension; and OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease; and OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease, both of which have completed Phase 2 clinical trials. Forward Looking Statements Any statements in this press release about future expectations, plans, and prospects for the Company, including the commercialization of DEXTENZA® or any of the Company’s products or product candidates; the development and regulatory status of the Company’s product candidates, such as the Company’s development of and prospects for approvability of OTX-TKI for the treatment of retinal diseases including wet AMD and diabetic retinopathy including the timing of planned pivotal clinical trials, OTX-TIC for the treatment of primary open-angle glaucoma or ocular hypertension, OTX-DED for the short-term treatment of the signs and symptoms of dry eye disease, and OTX-CSI for the chronic treatment of dry eye disease; the Company’s plans to advance the development of its product candidates or preclinical programs; the Company’s ability to fund the planned and future development of its product candidates, whether through strategic alliances or other fundraising; the potential utility of any of the Company’s product candidates; the size of potential markets for the Company’s product candidates; 2023 financial guidance, including estimated net product revenue; the sufficiency of the Company’s cash resources; and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend", "goal," "may", "might," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company’s preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the timing and costs involved in commercializing DEXTENZA or any product or product candidate that receives regulatory approval, including the conduct of post-approval studies, the ability to retain regulatory approval of DEXTENZA or any product or product candidate that receives regulatory approval, the ability to maintain and the sufficiency of product, procedure and any other reimbursement codes for DEXTENZA, the initiation, timing, conduct and outcomes of clinical trials, whether clinical trial data will be indicative of the results of subsequent clinical trials in the same or other indications or that interim data will be indicative of the full data from a clinical trial, uncertainties as to the timing and availability of data from clinical trials and expectations for regulatory submissions and approvals, the Company’s ability to enter into and perform its obligations under collaborations and the performance of its collaborators under such collaborations, the Company’s scientific approach and general development progress, the availability or commercial potential of the Company’s product candidates, the Company’s ability to meet supply demands, the Company’s ability to generate its projected net product revenue and in-market sales on the timeline expected, if at all, the sufficiency of cash resources, the Company’s existing indebtedness, the ability of the Company’s creditors to accelerate the maturity of such indebtedness upon the occurrence of certain events of default, the severity and duration of the COVID-19 pandemic including its effect on the Company’s revenues and relevant regulatory authorities’ operations, any additional financing needs, the Company’s ability to recruit and retain key personnel, and other factors discussed in the “Risk Factors” section contained in the Company’s quarterly and annual reports on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date of this press release. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release. InvestorsOcular TherapeutixDonald NotmanChief Financial Officerdnotman@ocutx.com or ICR WestwickeChris Brinzey, 339-970-2843Managing Directorchris.brinzey@westwicke.com

Phase 1Phase 2Drug Approval

17 Apr 2023

·www.drugs.com

Get Pain Relief With the Most Common Arthritis Medications

MONDAY, April 17, 2023 -- Arthritis is a common disease that causes pain and inflammation in different body joints, making it difficult to enjoy everyday tasks and physical activity. Fortunately, there are many different medications for arthritis. Depending on what type of arthritis you have and its severity, an arthritis medication may help you manage pain and other symptoms. Here is a breakdown of the most common arthritis medications, how they work and their potential side effects. The Arthritis Foundation lists the following as the medications used to treat arthritis: Analgesics including acetaminophen (Tylenol) and opioids Nonsteroidal anti-inflammatory drugs (NSAIDs) Corticosteroids Disease-modifying antirheumatic drugs (DMARDs) including biologics and targeted DMARDs Analgesics The Arthritis Foundation reports that analgesics may help with mild to moderate pain, but they will not help with the inflammation associated with arthritis. Analgesics work in the nervous system and alter how your brain perceives pain. They can be used to treat the pain associated with any type of arthritis, although more effective options are available. Analgesics can be opioid, non-opioid or a combination. Common analgesics are: Acetaminophen (Tylenol) Codeine Oxycodone Fentanyl Hydrocodone Potential side effects: Kidney damage Liver damage Addiction Constipation Gastrointestinal bleeding Use caution when taking these medications; take only as prescribed. NSAIDs NSAIDs work by blocking prostaglandin. According to the Cleveland Clinic , one role prostaglandins play is forming clots and causing inflammation at the site of an injury. NSAIDs are used to treat the pain and inflammation associated with rheumatoid arthritis and osteoarthritis . Common over-the-counter (OTC) NSAIDs are: Aspirin (Bayer, St. Joseph, Anacin, Excedrin and more) Ibuprofen (Motrin, Advil) Naproxen sodium (Aleve) Prescription NSAIDs are: Celecoxib (Celebrex) Diclofenac (Voltaren, available by brand name in topical form) Fenoprofen (Nalfon) Indomethacin (Indocin, available by brand name in liquid form) Ketorolac tromethamine (Toradol) Meclofenamate sodium (Meclomen) Diflunisal (Dolobid) Tolmetin (Tolectin) Ketoprofen (Orudis) Flurbiprofen (Ansaid) Potential side effects of NSAIDs are: Increased risk of stomach and bowel issues like ulcers and bleeding Increased risk of stroke Heart problems Stomach pain Nausea Diarrhea/constipation Corticosteroids According to the Arthritis Foundation , corticosteroids mimic cortisol, a hormone your body produces naturally. They are used to treat inflammatory types of arthritis, including rheumatoid arthritis and psoriatic arthritis. They are great for short-term relief of inflammation but are not recommended for long-term use because of their side effects. Your doctor may prescribe a lower dose if you require them for long-term use. Common corticosteroids: Prednisone (Deltasone, Prednicot, Cotolone) Prednisolone (Orapred, Omnipred) Cortisone (Cortone) Hydrocortisone (Cortef, Hydrocort) Triamcinolone (Aristocort) Dexamethasone (Decadron) Common side effects of corticosteroids: Blood sugar spikes Weight gain Bone loss Risk of cataracts High blood pressure Infections Mood changes DMARDs The Arthritis Foundation says that DMARDs work with the body to “stop or slow the disease process in inflammatory forms of arthritis.” They work by blocking inflammation. There are many different DMARDs on the market, and they all have different ways of working in the body. Conventional DMARDs work by broadly suppressing the immune system. Often they are used in combination with other therapies. Targeted DMARDs block specific pathways inside immune cells. Biologic DMARDs are produced by live cells and work on specific immune proteins called cytokines. Common DMARDs: Apremilast (Otezla) Baricitinib (Olumiant) Cyclophosphamide (Cytoxan) Cyclosporine (Gengraf, Neoral) Hydroxychloroquine (Plaquenil) Leflunomide (Arava) Methotrexate (Otrexup, Rasuvo, RediTrex) Mycophenolate mofetil (CellCept) Sulfasalazine (Azulfidine) Tofacitinib (Xeljanz, Xeljanz XR) According to the Cleveland Clinic , common side effects of traditional DMARDs include: Loss of appetite Nausea Diarrhea Abdominal pain Rash, allergic reaction Liver problem Increased risk of infection Low blood cell counts Common side effects of biologic DMARDs include: Increased risk of common and serious infections Reactivation of tuberculosis, herpes zoster, and hepatitis B and C Increased cholesterol levels, increased liver enzymes and low blood cell counts Increased risk of clotting When prescribed DMARDs, inform your doctor of any other medications, including over-the-counter medicines, you are taking to avoid drug interactions. Some of these medications can cause teratogenicity (defects in a developing fetus.) Writing recently in the Journal of the American Academy of Physician Assistants (JAAPA ), physician assistant Michelle DiBiase and Dr. Samantha Kohn remind people that "The mainstay of pharmacologic therapy is early intervention with use of nonbiologic and biologic DMARDs together with adjunctive medications such as NSAIDs, oral and intra-articular corticosteroids, and analgesic medications, including opioids." Your primary care provider or rheumatologist will work closely with you to determine which medications are best for your treatment. It is vital to keep them apprised of any side effects and let them know if the treatment is ineffective. They can work with you to find a treatment that helps relieve the pain and inflammation caused by arthritis. Posted April 2023

Drug Approval

100 Deals associated with Prednisolone Acetate

External Link

KEGG	Wiki	ATC	Drug Bank
D00980	Prednisolone Acetate	D07XA02 D07AA03 S02BA03 A07EA01 C05AA04 S03BA02 S01CB02 H02AB06 R01AD02 S01BA04	DB15566

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Ocular inflammation	Japan	Shionogi Pharma Co., Ltd.	16 Aug 1957

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Inflammation	Discovery	United States	Schering Corp.	22 May 1955

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06679153 (NEWS) Manual	Phase 2	Non-infectious anterior uveitis	86	0.5% VVN461	(dllckxpcsy) = mnzzluadzk onttzmtqeu (evteregkxf ) Met View more	Non-inferior	03 Jan 2025
				1.0% VVN461	(dllckxpcsy) = tegcampjlo onttzmtqeu (evteregkxf ) Met View more
APAO2024	Not Applicable	Keratitis, Dendritic	-	Oral Acyclovir 400mg	rudxlueluw(wzxhkockgw) = vejurrapao lgtwnsvjaf (wclsbijqrk )	-	22 Feb 2024
				Prednisolone Acetate Eye Drops	rudxlueluw(wzxhkockgw) = cwohokfkuv lgtwnsvjaf (wclsbijqrk )
NCT02406209 (CTgov)	Phase 2	Non-infectious anterior uveitis	45	NS2 (NS2 Ophthalmic Drops (0.5%))	crimgzsczo(ltwvfddala) = gbzgcgdkrp lisydxibmc (kzoodipstm, zjzihskshy - wcowvotbbn) View more	-	27 Mar 2023
				Pred Forte+NS2 (NS2 (0.5%) and Pred Forte® (0.1%) Ophthalmic Drops)	crimgzsczo(ltwvfddala) = qhztczktgc lisydxibmc (kzoodipstm, rpjvrajuto - gnkgnkmcjr) View more
NCT03578276 (CTgov)	Phase 4	Cataract	35	prednisolone acetate+gatifloxacin+bromfenac (LessDrops)	qpntrddthx(aczkqptovn) = qovxfvjjci ehxgpleptq (llurqtspan, kwdjiezspr - xpgqqkvhoi) View more	-	10 Jun 2022
				Prednisolone acetate 1% ophthalmic suspension+Gatifloxacin Ophthalmic+Bromfenac 0.075% Oph Solution (Standard of Care)	qpntrddthx(aczkqptovn) = otixdzwrsg ehxgpleptq (llurqtspan, opuckqjurl - fcpibmgwlt) View more
ARVO2021	Not Applicable	-	-	Loteprednol etabonate (submicron) ophthalmic gel 0.38%	oukcqypkvl(wpjjuxvuij) = njqkozxcpp rmevbfqtvm (uxiyjdprrm, 1.3)	-	01 Jun 2021
				Prednisolone acetate ophthalmic suspension 1.0%	oukcqypkvl(wpjjuxvuij) = gaxyvskvdj rmevbfqtvm (uxiyjdprrm, 1.39)
NCT03123614 (CTgov)	Phase 4	Corneal Opacity	131	Loteprednol Etabonate 0.5% Oph Gel (Loteprednol Etabonate 0.5% Oph Gel)	cxudmjhilg(glfxaqssvw) = soshdowwep qehfmpeuju (ozezxruvec, vdafyoyskr - gmndlnwixp) View more	-	21 Dec 2020
				Prednisolone Acetate 1% Oph Susp (Prednisolone Acetate 1% Oph Susp)	cxudmjhilg(glfxaqssvw) = saufdslawb qehfmpeuju (ozezxruvec, xtajshrqxj - ocqmtbshzl) View more
NCT00699803 (CTgov)	Phase 2	Cataract	64	T-PRED (T-Pred)	qdynenazar(cmtbumyssw) = wtdsqfhoxq wpcimtiexn (ecpcialexr, curgabeuqt - qlqbokauvh) View more	-	03 Sep 2020
				Pred Forte (Pred Forte)	qdynenazar(cmtbumyssw) = qcvsznbvsl wpcimtiexn (ecpcialexr, qmqcumvili - pcggttbtxl) View more
NCT03693989 (phase III, ARVO2020)	Phase 3	Post procedural inflammation	171	Difluprednate 0.05%	(vvqeosmwnv) = uurlncywnu flyqrqytvi (sljsswnjfw ) View more	Positive	01 Jun 2020
				Prednisolone acetate 1%	(vvqeosmwnv) = mzgzpumaau flyqrqytvi (sljsswnjfw ) View more
NCT02819908 (CTgov)	Phase 4	Ophthalmologic surgical procedures \| Post procedural inflammation	25	triamcinolone acetonide+moxifloxacin hydrochloride+vancomycin (Imprimis Dropless)	isghsjyczl(uztgdsfzbh) = qdrsbbzukx zkjpjgwcvt (wybxahlzgv, qjvorfiakt - fqxppelcpz) View more	-	09 Mar 2020
				prednisolone acetate+ketorolac tromethamine +moxifloxacin hydrochloride (Imprimis Less Drops)	isghsjyczl(uztgdsfzbh) = cngrxoxctw zkjpjgwcvt (wybxahlzgv, thkpmhxjqt - xzmbnooppw) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Prednisolone Acetate

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation